Mayinglong Pharmaceutical Group (600993): A traditional brand of Traditional Chinese Medicine in the field of proctology, adhering to tradition and innovating for development.

With a classic heritage of over 400 years, focusing on anal and rectal medications, the development spans multiple fields. Mayinglong Pharmaceutical Group was founded in 1582 and has become a "Chinese Time-Honored Brand" with a continuous operation of 440 years. The company's main Business focuses on anal and rectal health medications.

HAITONG SECDec 22, 2024 11:52

HAITONG INT'L: Bullish on the bottom reversal of the Traditional Chinese Medicine Industry, with the State-owned Enterprise Reform and mergers and acquisitions resonating in development.

As aging continues to intensify, the demand in the Silver economy and chronic disease medication-related fields is viewed as Bullish.

Zhitong FinanceDec 13, 2024 14:47

Mayinglong Pharmaceutical Group's MYL Ointment Gets Regulatory Approval for Clinical Trials

MT NewswiresDec 10, 2024 18:57

Mayinglong Pharmaceutical Group (600993.SH): MYL ointment (Tiger musk hemostatic analgesic ointment, tentatively named) has been approved for clinical trials.

Mayinglong Pharmaceutical Group (600993.SH) issued an announcement, stating that recently, the company received approval from the National Medical Products Administration for a signed notice concerning...

Zhitong FinanceDec 6, 2024 15:49

Express News | Mayinglong Pharmaceutical Group: Received the Notice of Approval for Clinical Drug Trials.

BreakingsDec 6, 2024 15:47

Mayinglong Pharmaceutical Group (600993): Inheriting and innovating to keep the old traditional chinese medicine brand vibrant; first coverage with a buy rating.

As a market and brand leader who adheres to inheritance and innovation, we maintain sustainable business growth; we expect the company's revenue and profit growth rate CAGR to reach 17.7%/20.1% for 2023-26E; effective channel management is like treating hemorrhoids.

Huaxing SecuritiesNov 20, 2024 00:00